252 related articles for article (PubMed ID: 34957531)
1. Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework.
Langford B; Diamantopoulos A; Maher TM; Inoue Y; Rohr KB; Baldwin M
Adv Ther; 2022 Feb; 39(2):1045-1054. PubMed ID: 34957531
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
3. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials.
Hoffmann-Vold AM; Volkmann ER; Allanore Y; Assassi S; de Vries-Bouwstra JK; Smith V; Tschoepe I; Loaiza L; Kanakapura M; Distler O
Lancet Rheumatol; 2022 Oct; 4(10):e679-e687. PubMed ID: 38265966
[TBL] [Abstract][Full Text] [Related]
5. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
Makino S
Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
[TBL] [Abstract][Full Text] [Related]
6. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Magnusson MO; Freiwald M
Respir Med; 2021; 180():106369. PubMed ID: 33798871
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.
Cottin V; Martinez FJ; Jenkins RG; Belperio JA; Kitamura H; Molina-Molina M; Tschoepe I; Coeck C; Lievens D; Costabel U
Respir Res; 2022 Apr; 23(1):85. PubMed ID: 35392908
[TBL] [Abstract][Full Text] [Related]
8. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
[TBL] [Abstract][Full Text] [Related]
9. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Sarr C; Freiwald M
BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
[TBL] [Abstract][Full Text] [Related]
10. Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs).
Joannes A; Voisin T; Morzadec C; Letellier A; Gutierrez FL; Chiforeanu DC; Le Naoures C; Guillot S; De Latour BR; Rouze S; Jaillet M; Crestani B; Wollin L; Jouneau S; Vernhet L
Pulm Pharmacol Ther; 2023 Dec; 83():102267. PubMed ID: 37972706
[TBL] [Abstract][Full Text] [Related]
11. Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial.
Ogura T; Suda T; Inase N; Nishioka Y; Azuma A; Okamoto M; Takizawa A; Ito T; Rohr KB; Inoue Y
Respir Investig; 2022 Nov; 60(6):787-797. PubMed ID: 35927208
[TBL] [Abstract][Full Text] [Related]
12. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.
Lancaster L; Crestani B; Hernandez P; Inoue Y; Wachtlin D; Loaiza L; Quaresma M; Stowasser S; Richeldi L
BMJ Open Respir Res; 2019; 6(1):e000397. PubMed ID: 31179001
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
Inoue Y; Suda T; Kitamura H; Okamoto M; Azuma A; Inase N; Kuwana M; Makino S; Nishioka Y; Ogura T; Takizawa A; Ugai H; Stowasser S; Schlenker-Herceg R; Takeuchi T
Respir Med; 2021 Oct; 187():106574. PubMed ID: 34564020
[TBL] [Abstract][Full Text] [Related]
14. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
[TBL] [Abstract][Full Text] [Related]
15. Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases.
Bonella F; Cottin V; Valenzuela C; Wijsenbeek M; Voss F; Rohr KB; Stowasser S; Maher TM
Adv Ther; 2022 Jul; 39(7):3392-3402. PubMed ID: 35576048
[TBL] [Abstract][Full Text] [Related]
16. The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: A subset analysis of the INBUILD trial.
Inoue Y; Kitamura H; Okamoto M; Ogura T; Nishioka Y; Kuwana M; Taniguchi A; Ito T; Rohr KB; Suda T
Respir Investig; 2024 Jul; 62(4):589-596. PubMed ID: 38692040
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial.
Inoue Y; Wells AU; Song JW; Xu Z; Kitamura H; Suda T; Okamoto M; Müller H; Coeck C; Rohr KB; Kolb M; Brown KK
Respirology; 2023 May; 28(5):465-474. PubMed ID: 36642509
[TBL] [Abstract][Full Text] [Related]
18. [Use of antifibrotic drugs in interstitial lung disease].
Kreutz CP; Gesierich W; Behr J; Kneidinger N
Dtsch Med Wochenschr; 2022 Oct; 147(21):1383-1390. PubMed ID: 36279864
[TBL] [Abstract][Full Text] [Related]
19. The natural history of progressive fibrosing interstitial lung diseases.
Brown KK; Martinez FJ; Walsh SLF; Thannickal VJ; Prasse A; Schlenker-Herceg R; Goeldner RG; Clerisme-Beaty E; Tetzlaff K; Cottin V; Wells AU
Eur Respir J; 2020 Jun; 55(6):. PubMed ID: 32217654
[TBL] [Abstract][Full Text] [Related]
20. Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study.
Joung KI; Park H; Park S; Shin JY; Kim YH
BMC Pulm Med; 2023 Mar; 23(1):98. PubMed ID: 36949407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
